Mezzasalma Advisors LLC Sells 756 Shares of Eli Lilly and Company $LLY

Mezzasalma Advisors LLC lowered its stake in Eli Lilly and Company (NYSE:LLY) by 12.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,365 shares of the company’s stock after selling 756 shares during the period. Eli Lilly and Company makes up approximately 1.0% of Mezzasalma Advisors LLC’s holdings, making the stock its 21st largest holding. Mezzasalma Advisors LLC’s holdings in Eli Lilly and Company were worth $4,093,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Sumitomo Mitsui Financial Group Inc. purchased a new position in Eli Lilly and Company in the 2nd quarter worth approximately $27,000. Evolution Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company in the second quarter worth $29,000. Steph & Co. raised its holdings in Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares during the last quarter. Financial Gravity Companies Inc. purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at $31,000. Finally, Bare Financial Services Inc boosted its position in Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 29 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,077.26 on Monday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99. The stock’s 50 day simple moving average is $986.75 and its two-hundred day simple moving average is $841.60. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The stock has a market cap of $1.02 trillion, a price-to-earnings ratio of 52.70, a PEG ratio of 1.09 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the prior year, the company earned $1.18 EPS. The business’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is 29.35%.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of analyst reports. Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research report on Tuesday, December 2nd. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. BMO Capital Markets set a $1,200.00 price target on Eli Lilly and Company in a research report on Thursday, December 4th. Leerink Partners reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, December 18th. Finally, The Goldman Sachs Group boosted their target price on Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $1,155.36.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.